Translating patient-derived xenograft tumor growth inhibition data to clinical dose–response prediction for antibody-drug conjugates: a QSP modeling approach

Introduction Antibody-drug conjugates (ADCs) represent a transformative oncology modality, yet existing model-informed drug development (MIDD) methods have not yet demonstrated satisfactory predictive performance for clinical efficacy. Methods Here we develop a model-based framework that integrated patient-derived xenograft (PDX) data with quantitative systems pharmacology (QSP) modeling and virtual patient population simulations to predict clinical patient response in terms of objective response rates (ORR). The QSP model mechanistically incorporated compartmental ADC metabolism and pharmacokinetic distribution, receptor-mediated ADC tumor cell disposition, payload bystander effect and tumor killing. Data of two HER2-ADCs, trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) were used as case demonstrations. Results The QSP model framework was successfully parameterized to capture tumor growth inhibition dynamics across 16 different HER2-expressing PDX models, and by formulating model-based virtual patients, it is shown that simulation-predicted clinical ORR for T-DXd can match with the ranges observed across actual T-DXd trials. Simulated dose–ORR relationship identified a dosage of about 5-6 mg/kg Q3W for T-DXd as the optimal clinical dose, beyond which further dose escalation yields diminishing returns, and the clinical utility and generalizability of this framework is again verified using PDX-clinical data of T-DM1. Sequencing and bioinformatics analysis further suggested that immune plus fibrotic status in tumor microenvironment may together contribute to ADC efficacy stratification. Discussion In summary, this PDX-informed QSP modeling framework can serve as a translational tool to prospectively evaluate clinically dose-response relationships and design clinical dose escalation strategy for ADC drug development.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.1934056
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Translating patient-derived xenograft tumor growth inhibition data to clinical dose–response prediction for antibody-drug conjugates: a QSP modeling approach

Danyi Wen, Hongkui Chen, Wenyuan Nie, Xiaorong Gu et al.
1 links
Frontiers in Immunology
Monoclonal and Polyclonal Antibodies Research
article

Translating patient-derived xenograft tumor growth inhibition data to clinical dose–response prediction for antibody-drug conjugates: a QSP modeling approach

Danyi Wen, Hongkui Chen, Wenyuan Nie, Xiaorong Gu, Chen Zhao, Yumeng Zheng, Yiwen Ma, Yuan Gao, Qi Fu, Diandong Jiang
article en

Abstract

Introduction Antibody-drug conjugates (ADCs) represent a transformative oncology modality, yet existing model-informed drug development (MIDD) methods have not yet demonstrated satisfactory predictive performance for clinical efficacy. Methods Here we develop a model-based framework that integrated patient-derived xenograft (PDX) data with quantitative systems pharmacology (QSP) modeling and virtual patient population simulations to predict clinical patient response in terms of objective response rates (ORR). The QSP model mechanistically incorporated compartmental ADC metabolism and pharmacokinetic distribution, receptor-mediated ADC tumor cell disposition, payload bystander effect and tumor killing. Data of two HER2-ADCs, trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) were used as case demonstrations. Results The QSP model framework was successfully parameterized to capture tumor growth inhibition dynamics across 16 different HER2-expressing PDX models, and by formulating model-based virtual patients, it is shown that simulation-predicted clinical ORR for T-DXd can match with the ranges observed across actual T-DXd trials. Simulated dose–ORR relationship identified a dosage of about 5-6 mg/kg Q3W for T-DXd as the optimal clinical dose, beyond which further dose escalation yields diminishing returns, and the clinical utility and generalizability of this framework is again verified using PDX-clinical data of T-DM1. Sequencing and bioinformatics analysis further suggested that immune plus fibrotic status in tumor microenvironment may together contribute to ADC efficacy stratification. Discussion In summary, this PDX-informed QSP modeling framework can serve as a translational tool to prospectively evaluate clinically dose-response relationships and design clinical dose escalation strategy for ADC drug development.

Frontiers in ImmunologyVol. 17
Jiangsu Province Hospital (CN), Nanjing Medical University (CN)
Good health and well-being
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon